Urgo Medical France

What Urgo Medical France does

Urgo Medical France is a French medical devices company specializing in advanced wound care, operating as Laboratoires Urgo (S.A.S., registered capital €13,987,328, RCS Dijon) under the Urgo Group umbrella. The company is headquartered in Chenôve (Bourgogne-Franche-Comté), manufactures compression bandages at a production site in Veauche (Loire), and operates an industrial/logistics facility in Chevigny-Saint-Sauveur. Its portfolio centers on the proprietary TLC-NOSF matrix technology (Technologie Lipido-Colloïde – Nano OligoSaccharide Factor), delivered through the UrgoStart Plus range (Border, Absorb, Compresse, Interface) for chronic wounds, complemented by the UrgoK2 bi-band compression system for venous leg ulcers and the UrgoTul interface and silver dressings. All major SKUs carry CE marks (BSI 2797) and full LPPR reimbursement (Social Security 60% + Mutual 40%) for specified indications including venous leg ulcers and neuro-ischemic diabetic foot ulcers.

The company serves healthcare professionals — doctors, nurses (including home-care and independent wound-care specialists), pharmacists, and hospitals — treating chronic and acute wounds in France, with no disclosed activity outside the French market despite the existence of sibling Urgo Medical sites in Spain, Germany, the UK, and the Netherlands. Go-to-market combines a direct field-sales force providing samples, clinical information, and protocol support with broad distribution through French pharmacies under reimbursement. Around this commercial core, Urgo operates an ecosystem of clinical evidence (40 studies, 70 publications, 26,000+ patients), KOL-led education (Chroniques de Plaies platform, webinars featuring named experts), digital tools (Healico wound care application), and an innovation pipeline (Genesis platform). The stated clinical performance claim — a +42% healing-rate improvement and 5 weeks of healing time saved versus dressings without TLC-NOSF — anchors both the value proposition and the regulatory/reimbursement narrative.

Name

Urgo Medical France

Legal name

Laboratoires Urgo

Website

https://urgomedical.fr

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Urgo Medical France is a French medical devices company that develops and sells TLC-NOSF-based advanced wound dressings, compression systems, and educational tools to French healthcare professionals treating chronic wounds, fully reimbursed under LPPR.

Ownership category

akta.pro rank

Product category

Advanced Wound Care Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Advanced Wound Dressings (Foam, Hydrocolloid, Alginate, Hydrogel, Film) (HLAHALAA)

akta.pro secondary industries

Compression Therapy & Lymphedema DME (Garments, Pneumatic Pumps) (HLAHAMAH), Hand Hygiene & Skin Antisepsis (Soaps, Sanitizers, Surgical Scrubs, CHG Prep) (HLAHANAE)

Keywords

• Advanced wound care
• Medical dressings
• Compression therapy
• Chronic wound healing
• Medical devices

Headquarters

HQ city

Chenôve

HQ country

France

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Medical Device Sales: Sale of wound care dressings and compression medical devices to healthcare professionals, pharmacies, and hospitals in France. Products are Class IIb and Class I medical devices reimbursed under French LPPR (Liste des Produits et Prestations Remboursables) at 60% Social Security + 40% Mutual insurance.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Urgo Medical France manufactures and sells advanced wound care medical devices, including the UrgoStart Plus range of hydrocellular dressings featuring proprietary TLC-NOSF (Technologie Lipido-Colloïde – Nano OligoSaccharide Factor) matrix technology, the UrgoK2 multi-layer bi-band compression system, and the UrgoTul line of interface and silver-impregnated dressings. Products are Class I and IIb CE-marked medical devices reimbursed under the French LPPR system and are sold to healthcare professionals (doctors, nurses, pharmacists) treating chronic wounds such as venous leg ulcers, diabetic foot ulcers, and pressure ulcers.

Product overview

Urgo Medical France is a French medical devices company specializing in advanced wound care and healing solutions. Their product portfolio centers on the TLC-NOSF (Technologie Lipido-Colloïde – Nano OligoSaccharide Factor) technology platform, featuring the UrgoStart Plus product range (Border, Absorb, Compresse, Interface) designed to address chronic wounds by reducing excess MMPs and promoting healing. Complementary products include the UrgoK2 bi-band compression system for venous leg ulcer treatment, and the UrgoTul product line (Interface and Argent/Ag) providing tulle-based wound contact layers with optional silver antimicrobial protection. The company also provides educational resources through the Chroniques de Plaies platform, webinars, and clinical guides for healthcare professionals.

Differentiator

Problem solved

Functional benefit

Brands

• UrgoStart Plus: Wound dressing product line featuring TLC-NOSF technology for chronic wound healing
• UrgoK2
• UrgoTul
• Chroniques de Plaies
• TLC-NOSF
• Genesis

Products and services

• UrgoStart Plus Border Hydrocellular adhesive dressing with high absorption capacity, poly-absorbent fibers, and TLC-NOSF matrix designed for chronic wounds including venous leg ulcers, diabetic foot ulcers, and pressure sores. Class IIb medical device, CE 2797, fully reimbursable under French LPPR.
• UrgoStart Plus Absorb Non-adhesive hydrocellular dressing with high absorption capacity, poly-absorbent fibers, and TLC-NOSF matrix for the management of exuding wounds.
• UrgoStart Plus Compresse Non-adhesive hydrocellular dressing with poly-absorbent fibers and TLC-NOSF matrix for wound management.
• UrgoStart Interface Interface dressing for atraumatic wound contact and protection during the healing process, leveraging TLC-NOSF technology.
• UrgoK2 Multi-type bi-band compression system with controlled pressure for the treatment of venous leg ulcers and lower limb edema, featuring a two-band system providing approximately 40mmHg pressure. Available in standard and latex-free versions. Class I medical device, BSI CE 2797, reimbursable under LPPR.
• UrgoTul Interface Interface dressing with tulle technology for atraumatic wound contact and maintenance of a moist wound healing environment.
• UrgoTul Argent (Ag) Silver-impregnated tulle dressing for management of infected or at-risk wounds, providing antimicrobial protection.

Quantifiable outcome

• +42% improvement in healing rate vs dressings without TLC-NOSF (17 studies, 10,203 wounds - Journal of Wound Care systematic review)
• +1 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Scale indicators5 records

Recent moves1 record

Expansion highlights5 records

Direct peers

• Coloplast: Danish specialist in wound care (Biatain, Comfeel) alongside ostomy and continence. Direct competitor in advanced foam and hydrocolloid dressings for chronic wounds, targeting the same HCP and home-care prescriber base across Europe.
• Mölnlycke Health Care: Swedish global leader in advanced wound care (Mepilex, Mepitel) and surgical solutions. Directly comparable to Urgo Medical France as a focused advanced wound dressings manufacturer serving hospitals and home-care nurses with similar foam/silicone dressings and chronic-wound focus.
• Hartmann Group: German-based medical products company with a strong wound care portfolio (Hydrocoll, Zetuvit, Cosmopor). Comparable to Urgo Medical France as a European advanced wound dressings specialist with similar reimbursement-driven, HCP-targeted go-to-market.
• Integra LifeSciences: US-based medical device company with a significant wound care and regenerative tissue portfolio (Integra Dermal Regeneration Template, AmnioExcel). Comparable to Urgo Medical France in advanced and biologic wound therapies targeting chronic wounds.
• ConvaTec: UK-listed wound, ostomy and continence company (Aquacel, Foam Lite). Directly comparable portfolio of advanced dressings and compression for chronic wounds, sold through similar pharmacy and hospital channels in Europe.

Broad incumbents

• B. Braun: German medical device and pharmaceutical group with a wound care line (Askina). Overlaps with Urgo Medical France in advanced dressings and is active in French hospital procurement, though wound care is one of many divisions.
• Smith & Nephew: UK-listed medical device major with a sizeable Advanced Wound Management division (Allevyn, PICO NPWT). Competes with Urgo Medical France in French hospitals and pharmacies across dressings and compression, but competes across many other orthopaedic and sports medicine categories as well.
• 3M Health Care: US diversified giant with a wound care and skin integrity portfolio (Tegaderm, V.A.C. therapy via KCI). Competes with Urgo Medical France across advanced dressings and negative pressure wound therapy, but as part of a much broader industrial and healthcare portfolio.

Emerging players

• MiMedx: US-listed regenerative medicine company focused on amniotic tissue allografts for wound care and surgical recovery. Comparable emerging alternative in advanced/regenerative chronic-wound healing competing for similar clinical use cases.

Regional players

• Laboratoires Brothier: French wound care specialist (Algostéril, Coalgan). Closely comparable French competitor in advanced and haemostatic wound dressings, focused on the French hospital and community-care market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/c/UrgoMedicalFrance
• LinkedInlinkedin.com/company/urgo-medical-france

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Urgo Medical France